The effects of high-dose ivermectin regimens on Onchocerca volvulus in onchocerciasis patients

被引:53
|
作者
Awadzi, K [1 ]
Attah, SK [1 ]
Addy, ET [1 ]
Opoku, NO [1 ]
Quartey, BT [1 ]
机构
[1] Hohoe Hosp, Onchocerciasis Chemotherapy Res Ctr, Hohoe, Ghana
关键词
onchocerciasis; Onchocerca volvulus; chemotherapy; ivermectin; efficacy; drug regimens; adult worms;
D O I
10.1016/S0035-9203(99)90305-X
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Ivermectin, at the standard dose of 150 mu g/kg bodyweight, does not kill the adult worms of Onchocerca volvulus and does not disrupt embryogenesis or spermatogenesis. Repeated standard doses, if maintained, arrest microfilarial production but result in only a mild-to-modest macrofilaricidal effect. We investigated whether high doses would effectively kill the adult worms, and whether cessation of microfilarial production could be reproduced by an equivalent, single, high dose. One hundred men participated in a double-blind placebo-controlled trial and received increasing doses of ivermectin from 150 mu g/kg to 1600 mu g/kg bodyweight. Nodules were excised at day 180 and examined by histopathology. Total doses of ivermectin up to 1600 mu g/kg were not significantly more effective than 150 mu g/kg. Moreover, they did not reproduce the marked inhibitory effects of the repeat standard-dose regimens on embryogenesis, nor the modest effect on adult worm viability, at comparable total doses. These effects may be functions of multiplicities of dosages rather than of the total dose. Our findings also suggest that repeated high-dose regimens are unlikely to be more effective than a similar number of 150 mu g/kg doses. This deficiency of ivermectin requires that the search for macrofilaricides remains a top priority.
引用
收藏
页码:189 / 194
页数:6
相关论文
共 50 条
  • [41] Safety of high-dose daptomycin in patients with severe renal impairment
    Tai, Chih-Hsun
    Shao, Chi-Hao
    Chen, Chen-You
    Lin, Shu-Wen
    Wu, Chien-Chih
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2018, 14 : 493 - 499
  • [42] Human Direct Skin Feeding Versus Membrane Feeding to Assess the Mosquitocidal Efficacy of High-Dose Ivermectin (IVERMAL Trial)
    Smit, Menno R.
    Ochomo, Eric O.
    Aljayyoussi, Ghaith
    Kwambai, Titus K.
    Abong'o, Bernard O.
    Bousema, Teun
    Waterhouse, David
    Bayoh, Nabie M.
    Gimnig, John E.
    Samuels, Aaron M.
    Desai, Meghna R.
    Phillips-Howard, Penelope A.
    Kariuki, Simon K.
    Wang, Duolao
    Ward, Stephen A.
    ter Kuile, Feiko O.
    CLINICAL INFECTIOUS DISEASES, 2019, 69 (07) : 1112 - 1119
  • [43] Assessment and comparison of acute cardiac toxicity during high-dose cyclophosphamide and high-dose etoposide stem cell mobilization regimens with N-terminal pro-B-type natriuretic peptide
    Ozkan, Hasan Atilla
    Bal, Cengiz
    Gulbas, Zafer
    TRANSFUSION AND APHERESIS SCIENCE, 2014, 50 (01) : 46 - 52
  • [44] Safety and Efficacy of a MEURI Program for the Use of High Dose Ivermectin in COVID-19 Patients
    Mayer, Marcos Alejandro
    Krolewiecki, Alejandro
    Ferrero, Alejandro
    Bocchio, Marcelo
    Barbero, Juan
    Miguel, Marcos
    Paladini, Ariel
    Delgado, Carlos
    Ojeda, Juan Ramon
    Elorza, Claudia
    Bertone, Ana
    Fleitas, Pedro Emanuel
    Vera, Gustavo
    Kohan, Mario Ruben
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [45] Clinical efficacy and safety of high-dose doripenem in Japanese patients with pneumonia
    Yatera, Kazuhiro
    Naito, Keisuke
    Noguchi, Shingo
    Akata, Kentarou
    Yamasaki, Kei
    Nishida, Chinatsu
    Kawanami, Toshinori
    Sakamoto, Noriho
    Kido, Takashi
    Ishimoto, Hiroshi
    Mukae, Hiroshi
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2016, 22 (03) : 137 - 142
  • [46] Risk Factors for Hepatic Toxicity of High-dose Methotrexate in Patients With Osteosarcoma
    Abe, Kentaro
    Maeda-Minami, Ayako
    Ishizu, Taku
    Iwata, Shintaro
    Kobayashi, Eisuke
    Shimoi, Tatsunori
    Kawano, Yohei
    Hashimoto, Hironobu
    Yamaguchi, Masakazu
    Furukawa, Tetsuya
    Miyazaki, Satoru
    Mano, Yasunari
    ANTICANCER RESEARCH, 2022, 42 (02) : 1043 - 1050
  • [47] Low-germ Diet in High-dose Therapy: a Risk for Patients
    Schmidt, L.
    Erickson, N. T.
    Reudelsterz, C.
    Rubin, D.
    Lambeck, A.
    Kopcke, U.
    Arends, J.
    Huebner, J.
    von Grundherr, Julia
    ERNAHRUNGS UMSCHAU, 2022, 69 (03): : M134 - M139
  • [48] Response to High-Dose Ifosfamide in Patients With Advanced/Recurrent Ewing Sarcoma
    Ferrari, S.
    del Prever, A. Brach
    Palmerini, E.
    Staals, E.
    Berta, M.
    Balladelli, A.
    Picci, P.
    Fagioli, F.
    Bacci, G.
    Vanel, D.
    PEDIATRIC BLOOD & CANCER, 2009, 52 (05) : 581 - 584
  • [49] The use of extrapolation based on modeling and simulation to support high-dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft-tissue infections
    Chan, Phylinda L. S.
    McFadyen, Lynn
    Quaye, Andrea
    Leister-Tebbe, Heidi
    Hendrick, Victoria M.
    Hammond, Jennifer
    Raber, Susan
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (06): : 551 - 563
  • [50] Tandem high-dose chemotherapy with topotecan–thiotepa–carboplatin and melphalan–etoposide–carboplatin regimens for pediatric high-risk brain tumors
    Jung Yoon Choi
    Hyoung Jin Kang
    Kyung Taek Hong
    Che Ry Hong
    Yun Jeong Lee
    June Dong Park
    Ji Hoon Phi
    Seung-Ki Kim
    Kyu-Chang Wang
    Il Han Kim
    Sung-Hye Park
    Young Hun Choi
    Jung-Eun Cheon
    Kyung Duk Park
    Hee Young Shin
    International Journal of Clinical Oncology, 2019, 24 : 1515 - 1525